NASDAQ:CLDX

Celldex Therapeutics (CLDX) Stock Price, News & Analysis

Celldex Therapeutics logo
$27.96 +0.41 (+1.49%)
Closing price 04:00 PM Eastern
Extended Trading
$27.90 -0.06 (-0.20%)
As of 05:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Celldex Therapeutics Stock (NASDAQ:CLDX)

Advanced

Key Stats

Today's Range
$27.16
▼
$28.54
50-Day Range
$27.53
▼
$39.18
52-Week Range
$22.33
▼
$45.14
Volume
750,528 shs
Average Volume
1.07 million shs
Market Capitalization
$2.20 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$64.08
Consensus Rating
Moderate Buy

Company Overview

Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops antibody-based treatments for inflammatory diseases and cancer. Its research focuses on targets involved in immune responses and the activity of mast cells.

The company’s lead candidate, barzolvolimab, is an antibody that targets the KIT receptor. Celldex is studying it for chronic urticaria and other conditions associated with mast-cell activity.

Celldex also has early-stage oncology programs that investigate antibody therapies designed to affect immune pathways. The company is headquartered in Hampton, New Jersey, and is led by co-founder Anthony Marucci, its president and chief executive officer.

AI Generated. May Contain Errors.

Celldex Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
39th Percentile Overall Score

CLDX MarketRank™: 
1.93005181347 of 5 stars

Celldex Therapeutics scored higher than 39% of companies evaluated by MarketBeat, and ranked 1429th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Celldex Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on no strong buy ratings, 11 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Celldex Therapeutics has a consensus price target of $64.08, representing about 129.8% upside from its current price of $27.89.

  • Amount of Analyst Coverage

    Celldex Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Celldex Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Celldex Therapeutics are expected to decrease in the coming year, from ($4.12) to ($4.21) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Celldex Therapeutics is -6.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Celldex Therapeutics is -6.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Celldex Therapeutics has a P/B Ratio of 3.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    13.34% of the float of Celldex Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Celldex Therapeutics has a short interest ratio ("days to cover") of 10.35, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Celldex Therapeutics has recently increased by 3.52%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Celldex Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Celldex Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Celldex Therapeutics has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.
  • MarketBeat Follows

    Only 2 people have added Celldex Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Celldex Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    5.20% of the stock of Celldex Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Celldex Therapeutics has minimal institutional ownership at this time.

  • Read more about Celldex Therapeutics' insider trading history.
Receive CLDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celldex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CLDX Stock News Headlines

HC Wainwright Has Strong Estimate for CLDX FY2026 Earnings
CFA: Bank of America Said THIS
On January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.tc pixel
See More Headlines

CLDX Stock Analysis - Frequently Asked Questions

Celldex Therapeutics' stock was trading at $27.16 on January 1st, 2026. Since then, CLDX stock has increased by 2.7% and is now trading at $27.89.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) released its earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.02) by $0.06. The biopharmaceutical company earned $400 thousand during the quarter, compared to the consensus estimate of $723 thousand.

Shares of Celldex Therapeutics reverse split before market open on Monday, February 11th 2019.The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 8th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Celldex Therapeutics' top institutional investors include State Street Corp (4.43%), Baker BROS. Advisors LP (3.27%), Goldman Sachs Group Inc. (2.06%) and Fisher Asset Management LLC (1.59%). Insiders that own company stock include Anthony S Marucci, Samuel Bates Martin, Richard M Wright, Elizabeth Crowley, Margo Heath-Chiozzi and Diane C Young.
View institutional ownership trends
.

Shares of CLDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Celldex Therapeutics investors own include Micron Technology (MU), Gilead Sciences (GILD), NVIDIA (NVDA), Advanced Micro Devices (AMD), Novavax (NVAX), ACADIA Pharmaceuticals (ACAD) and Tesla (TSLA).

Company Calendar

Last Earnings
11/05/2026
Today
11/19/2026
9th Annual Evercore ISI HealthCONx Conference
12/01/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CLDX
CIK
744218
Employees
198
Year Founded
1983

Price Target and Rating

High Price Target
$100.00
Low Price Target
$34.00
Potential Upside/Downside
+129.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.77
Research Coverage
13 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.30)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$258.76 million
Net Margins
N/A
Pretax Margin
-195,608.84%
Return on Equity
-52.66%
Return on Assets
-47.58%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.97
Quick Ratio
10.97

Sales & Book Value

Annual Sales
$158 thousand
Price / Sales
13,902.49
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$8.27 per share
Price / Book
3.38

Miscellaneous

Outstanding Shares
78,562,000
Free Float
74,477,000
Market Cap
$2.20 billion
Optionable
Optionable
Beta
1.04

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NASDAQ:CLDX) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners